Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Payables: 2020-2024

Historic Payables for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to $24.3 million.

  • Oncology Institute's Payables rose 4501.87% to $35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.6 million, marking a year-over-year increase of 4501.87%. This contributed to the annual value of $24.3 million for FY2024, which is 6857.72% up from last year.
  • Oncology Institute's Payables amounted to $24.3 million in FY2024, which was up 6857.72% from $14.4 million recorded in FY2023.
  • Oncology Institute's Payables' 5-year high stood at $24.3 million during FY2024, with a 5-year trough of $9.4 million in FY2022.
  • Moreover, its 5-year median value for Payables was $14.4 million (2023), whereas its average is $15.3 million.
  • As far as peak fluctuations go, Oncology Institute's Payables crashed by 3976.48% in 2022, and later surged by 6857.72% in 2024.
  • Annual analysis of 5 years shows Oncology Institute's Payables stood at $12.6 million in 2020, then rose by 23.06% to $15.6 million in 2021, then crashed by 39.76% to $9.4 million in 2022, then soared by 53.96% to $14.4 million in 2023, then skyrocketed by 68.58% to $24.3 million in 2024.
  • Its Payables stands at $24.3 million for FY2024, versus $14.4 million for FY2023 and $9.4 million for FY2022.